At a glance
ClinicalIndex Comparison RecordN/ACompleted· 306 enrolled
Drug / intervention
HepQuant SHUNT Liver Diagnostic Testcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
In Brief
A clinical study evaluating HepQuant SHUNT Liver Diagnostic Test for Chronic Liver Disease. Completed, enrolled 306 participants across 26 sites.
Detailed Summary
The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Liver Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartJan 2019
Primary CompletionMay 2021
Study CompletionOct 2022
TodayJul 2026
First PostedJul 12, 2018
Enrollment StartJan 23, 2019
Primary CompletionMay 7, 2021
Study CompletionOct 22, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.0 years ago
Interventions
HepQuant SHUNT Liver Diagnostic Testcombination
One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate